1
|
Maray I, Álvarez-Asteinza C, Fernández-Laguna CL, Macía-Rivas L, Carbajales-Álvarez M, Lozano-Blazquez A. Dose reduction and toxicity of lenalidomide-dexamethasone in multiple myeloma: A machine-learning prediction model. J Oncol Pharm Pract 2024; 30:1051-1056. [PMID: 37670612 DOI: 10.1177/10781552231200795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
PURPOSE Lenalidomide remains an effective drug for multiple myeloma, but it is often associated with adverse events and requires dose adjustments. The objective of this study was to propose a model for predicting whether a patient would require dose adjustment. METHODS This retrospective observational study included patients treated with lenalidomide and dexamethasone from June 2014 to September 2018 at a tertiary hospital. Demographic variables, patient functional status, disease, analytical data specific to myeloma, and treatment-related variables were collected. Univariate and machine learning (logistic regression and classification and regression trees model) analyses were also performed. Kaplan-Meier analysis was used to determine the time of toxicity onset. Only lenalidomide (and not dexamethasone) related dose reductions are included. RESULTS A total of 64 patients received lenalidomide-dexamethasone. 69% (44) required dose reduction or discontinuation of treatment due to lenalidomide-related adverse events. The median time between treatment beginning and lenalidomide dose reduction or discontinuation was 8.0 months (95% CI: 6.0-17.0). Age, platelet count, and neutrophil count were related to dose reduction in the univariate model. In the multivariate models, age and neutrophil count were significant in the logistic regression model, renal clearance, and neutrophil count in the classification and regression trees model. CONCLUSION Elderly patients and those with low bone marrow reserves are prone to dose-limiting adverse events. This study can aid in making follow-up, prophylaxis, and dosing decisions to achieve better pharmacotherapeutic results.
Collapse
Affiliation(s)
- Iván Maray
- Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | | | - Lola Macía-Rivas
- Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Ana Lozano-Blazquez
- Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain
| |
Collapse
|
2
|
Zeng L, Huang H, Qirong C, Ruan C, Liu Y, An W, Guo Q, Zhou J. Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life? J Clin Nurs 2023; 32:7247-7259. [PMID: 37303229 DOI: 10.1111/jocn.16791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 04/12/2023] [Accepted: 05/30/2023] [Indexed: 06/13/2023]
Abstract
AIMS AND OBJECTIVES To identify symptom clusters and examine their association with health-related quality of life. BACKGROUND Multiple myeloma patients undergoing chemotherapy suffer from disease symptoms and adverse effects during the course of the disease. However, single symptom management has little effect, and symptom management for these patients remains challenging. Symptom clusters open a new perspective and provide important clues for symptom management. DESIGN A cross-sectional study. METHOD Participants were invited to complete the Chinese version of the Memorial Symptom Assessment Scale and Quality of Life Questionnaire-core 30. Appropriate indicators were used for descriptive statistics. Principal component analysis was used to identify symptom clusters. Associations between symptom clusters and quality of life were examined with Pearson correlation coefficients, Pearson correlation matrix and multiple linear regression. This study was reported following the STROBE checklist. RESULTS A total of 177 participants were recruited from seven hospitals in this study. We identified self-image disorder, psychological, gastrointestinal, neurological, somatic and pain symptom clusters in multiple myeloma patients with chemotherapy. Approximately 97.65% of patients suffer from multiple symptom clusters. The pain, psychological and gastrointestinal symptom clusters have negatively influence on health-related quality of life. The strongest association was found with the pain symptom cluster. CONCLUSION Most of multiple myeloma patients suffer from multiple symptom clusters. When improving the multiple myeloma patients' health-related quality of life, the clinical staff should prioritise relieving the pain symptom cluster. RELEVANCE TO CLINICAL PRACTICE When multiple myeloma patients undergoing chemotherapy suffer from multiple symptom clusters, nurses should prioritise relieving the pain symptom cluster to improve their health-related quality of life. When drawing up and providing interventions, nurses should focus on the correlation among symptoms rather than single symptom. By relieving one symptom in a given cluster, other symptoms within the same symptom cluster may also be relieved.
Collapse
Affiliation(s)
- Lihong Zeng
- Xiangya School of Nursing, Central South University, Changsha, China
| | - Hui Huang
- The Third Xiangya Hospital, Central South University, Changsha, China
| | - Chen Qirong
- Xiangya School of Nursing, Central South University, Changsha, China
| | - Chunhong Ruan
- The Third Xiangya Hospital, Central South University, Changsha, China
| | - Yaqi Liu
- The Third Xiangya Hospital, Central South University, Changsha, China
| | - Wenhong An
- School of Health and Wellness, Panzhihua University, Sichuan, China
| | - Qinqin Guo
- Xiangya School of Nursing, Central South University, Changsha, China
| | - Jiandang Zhou
- The Third Xiangya Hospital, Central South University, Changsha, China
| |
Collapse
|
3
|
Pimentel M, Espinal O, Godinez F, Jimenez F, Martinez D, Mendoza N, Quintana A, Richmond JE, Romero E. Consensus Statement: Importance of Timely Access to Multiple Myeloma Diagnosis and Treatment in Central America and the Caribbean. J Hematol 2022; 11:1-7. [PMID: 35356635 PMCID: PMC8929200 DOI: 10.14740/jh971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Accepted: 02/14/2022] [Indexed: 11/11/2022] Open
Abstract
Background In Central America and the Caribbean, multiple myeloma (MM) patients face significant barriers to diagnosis and treatment. The aim of this study is to describe the current situation of MM in the region, discuss the current barriers to timely diagnosis and proper treatment, and develop consensus recommendations to address these issues. Methods Nine experts from five countries took part in a virtual consensus meeting on MM in Central America and the Caribbean. During the meeting, experts analyzed the disease burden, the current conditions for disease management, and access to treatment in the region. The participants reached a consensus on the extent of the problem and the necessary measures. Results Hard evidence on the incidence and prevalence of MM in the region is scarce, but the experts perceive an increase in MM cases. The lack of data on the direct and indirect costs at the local and regional levels obscures the impact of the disease and limits awareness among decision-makers. Most patients are diagnosed late and face long waiting times and geographical barriers to access treatment. Access to efficacious innovative therapies that increase survival time is limited due to access barriers within health systems. Conclusions There was consensus on five recommendations: 1) to generate evidence; 2) to educate the public; 3) to increase timely diagnosis and facilitate access to treatment; 4) to promote interaction, collaboration, and participation among all sectors involved in the decision-making process; and 5) to guarantee timely access to new therapies.
Collapse
Affiliation(s)
- Mayra Pimentel
- Department of Hematology, Instituto Nacional del Cancer Rosa Emilia Tavares, Santo Domingo, Dominican Republic
| | - Ondina Espinal
- Department of Hematology, Hospital Jose Maria Cabral and Clinica Corominas, Santiago De Los Caballeros, Dominican Republic
| | - Francisco Godinez
- Department of Hematology, Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala
| | - Fabian Jimenez
- Department of Hematology, Hospital San Juan de Dios, San Jose, Costa Rica
| | - Darwin Martinez
- Department of Hematology, Hospital Escuela and Instituto Hondureno de Seguridad Social, Tegucigalpa, Honduras
| | - Ninotchka Mendoza
- Complejo Hospitalario Doctor Arnulfo Arias Madrid, Panama City, Panama
| | | | - Juan Enrique Richmond
- Department of Hematology-Oncology, Hospital Calderon Guardia, Universidad de Costa Rica, San Jose, Costa Rica
| | - Esmedalys Romero
- Department of Hematology, Hospital Salvador de Gautier, Centro Medico Moderno, Dominican Society of Hematology, Santo Domingo, Dominican Republic
| |
Collapse
|
4
|
Mansilla C, Soria E, Vallejo M, Valiente A, Perez-Juana A, Zabalza A, Hurtado G, Sala F, Ramírez N. Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma. Transl Oncol 2018; 11:647-652. [PMID: 29604510 PMCID: PMC6054590 DOI: 10.1016/j.tranon.2018.02.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 02/12/2018] [Accepted: 02/12/2018] [Indexed: 12/17/2022] Open
Abstract
Multiple myeloma (MM) is a very heterogeneous disease, characterized by multiple cytogenetic aberrations on plasma cells (PC) that have been traditionally used to predict the outcome of the disease. A mayor issue on the analysis of PC is the sometimes low infiltration of these cells in the bone marrow that hampers cytogenetic studies. To solve this problem we have optimized a selection strategy based on PC immunomagnetic isolation that has allowed us to lower to 1% the minimal PC infiltration requirement without loss of purity, enabling to perform genetic analysis. In this study, we have analyzed 153 bone marrow samples of patients suspected of MM, collected from February 2015 to May 2017 by the Genetics service of the Complejo Hospitalario de Navarra. Clinical characteristics of the patients and PC immunophenotyping, conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) analyses have been assessed on these samples. In our cohort 90% of the samples had cytogenetic abnormalities, among them 50% presented immunoglobulin rearrangements, 41.9% showed 1q gains, 29.7% showed 1p deletions and 33% presented TP53 deletion.
Collapse
Affiliation(s)
- Cristina Mansilla
- Oncohematology Research Group, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, IdiSNA
| | - Elena Soria
- Oncohematology Research Group, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, IdiSNA
| | - Miren Vallejo
- Oncohematology Research Group, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, IdiSNA
| | - Alberto Valiente
- Genetics Service, Complejo Hospitalario de Navarra, IdiSNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Aránzazu Perez-Juana
- Genetics Service, Complejo Hospitalario de Navarra, IdiSNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Amaya Zabalza
- Oncohematology Research Group, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, IdiSNA; Hematology Department, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Guillermina Hurtado
- Cytometry Service, Hematology Department, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Francisco Sala
- Cytometry Service, Hematology Department, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Natalia Ramírez
- Oncohematology Research Group, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, IdiSNA.
| |
Collapse
|
5
|
García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica 2015; 100:1207-13. [PMID: 26069291 DOI: 10.3324/haematol.2015.128439] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Accepted: 05/29/2015] [Indexed: 11/09/2022] Open
Abstract
This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008.
Collapse
Affiliation(s)
| | - Albert Oriol
- ICO - Hospital Germans Trias i Pujol, Fundació Josep Carreras, Spain
| | | | - Javier de la Rubia
- Hospital Universitario La Fe and Universidad Católica de Valencia, Spain
| | | | | | | | - Ana I Teruel
- Hospital Clínico Universitario de Valencia, Spain
| | | | | | - Paz Ribas
- Hospital Universitario Dr. Peset de Valencia, Spain
| | - Joan Bargay
- Hospital Son Llàtzer de Palma de Mallorca, Spain
| | | | - Miquel Granell
- Hospital de la Santa Creu i Sant Pau de Barcelona, Spain
| | - Enrique M Ocio
- Hospital Universitario de Salamanca-IBSAL, IBMCC (USAL-CSIC), Spain
| | - Josep M Ribera
- ICO - Hospital Germans Trias i Pujol, Fundació Josep Carreras, Spain
| | | | - María V Mateos
- Hospital Universitario de Salamanca-IBSAL, IBMCC (USAL-CSIC), Spain
| | | |
Collapse
|
6
|
Li W, Wang Y, Song Y, Xu L, Zhao J, Fang B. A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line. Oncol Lett 2015; 9:1719-1724. [PMID: 25789029 PMCID: PMC4356419 DOI: 10.3892/ol.2015.2946] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2014] [Accepted: 01/13/2015] [Indexed: 11/12/2022] Open
Abstract
Curcumin is an inexpensive, natural plant ingredient with protease inhibitor effects. The present study aimed to analyze the inhibitory effects of curcumin on the multiple myeloma (MM) RPMI 8226 cell line, and examine the underlying mechanism that promotes the apoptosis of RPMI 8226 cells. A growth curve was constructed in order to observe the relative growth velocity, and MTT was used to analyze the effect of different concentrations of curcumin on inhibiting the proliferation of the RPMI 8226 cells. The mRNA expression of the p53, Bax and MDM2 genes was detected using quantitative polymerase chain reaction. The expression of p53 protein in the MM RPMI 8226 cells following treatment with curcumin was detected by western blotting and ELISA. Curcumin inhibited the proliferation of the MM RPMI 8226 cells in a dose- and time-dependent manner. In the MM RPMI 8226 cells treated with curcumin, the expression of the p53 and Bax genes was upregulated, while the expression of the MDM2 gene was downregulated. p53 protein expression was higher in the curcumin experimental group compared with the control group. Subsequent to treatment with curcumin, the growth of the MM RPMI 8226 cell line was inhibited in a concentration- and time-dependent manner. In the MM RPMI 8226 cells treated with curcumin, p53 protein levels were upregulated, which suggested that curcumin may promote the apoptosis of MM cells by upregulating p53 protein expression.
Collapse
Affiliation(s)
- Wei Li
- Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, P.R. China
| | - Yaomei Wang
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, P.R. China ; Laboratory of Membrane Biology, New York Blood Center, New York, NY, USA
| | - Yongping Song
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
| | - Linping Xu
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
| | - Junmei Zhao
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
| | - Baijun Fang
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
| |
Collapse
|
7
|
The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study. Rev Clin Esp 2013. [DOI: 10.1016/j.rceng.2013.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Ríos R, González-Silva M, Molina E, García-Fernández JR, Clavero ME, Durán JM, López-Berenguel F, Romero MM, Jiménez-Moleón JJ, Sánchez MJ, Sáinz J, Jurado M. The impact of the type of hospital on survival of multiple myeloma patients: the MICORE study. Rev Clin Esp 2013; 213:330-5. [PMID: 23562426 DOI: 10.1016/j.rce.2013.02.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Revised: 01/17/2013] [Accepted: 02/10/2013] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To analyze the impact of the type of hospital in overall survival of multiple myeloma patients. PATIENTS AND METHOD A survival analysis was performed of all patients (n=431) diagnosed in 5 public hospitals (4 community hospitals and one university hospital) during the period 1993-2006. RESULTS Patients attended to in community hospitals differ significantly from those seen in the university hospital in the following variables: mean age (70 years [31-92] versus 67.9 (35-91), P=.038); percentage of stage iii patients (62.6% versus 69.1%, P=.033), and percentage of patients who had autologous stem cell transplant (8.2% versus 18.2%, P=.026). The variables associated with mortality in the multivariate analysis were age (P<.001), stage (iii versus i; P=.03) and renal failure (P=.04). The type of hospital did not reach statistical significance (hazard ratio of 0.72 (95% confidence interval 0.48-1.07), P=.1]. CONCLUSIONS The type of hospital is not significantly associated with mortality in multiple myeloma patients. These data support our current model of health care, in which the community hospitals are responsible for the primary care of these patients, in a coordinated work with the university hospital.
Collapse
Affiliation(s)
- R Ríos
- Servicio de Hematología-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, España; Servicio de Hematología-Hemoterapia, Hospital Valle de los Pedroches, Pozoblanco, Córdoba, España.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
García-Sanz R, Alegre A, Capote FJ, Hernández JM, Rosiñol L, Rubia JDL, Sureda A, Arriba FD, Bargay J, Díaz Mediavilla J, García-Laraña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel J, Bladé J. [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]. Med Clin (Barc) 2009; 134:268-78. [PMID: 19863972 DOI: 10.1016/j.medcli.2009.07.040] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2009] [Revised: 07/24/2009] [Accepted: 07/30/2009] [Indexed: 01/11/2023]
Affiliation(s)
- Ramón García-Sanz
- Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, España.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|